GH Research (GHRS) Expected to Release Quarterly Earnings on Thursday

GH Research (NASDAQ:GHRS) is expected to be announcing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect GH Research to post earnings of ($0.3122) per share for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 6, 2026 at 12:30 PM ET.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.06. On average, analysts expect GH Research to post ($1.20) EPS for the current fiscal year and ($2.10) EPS for the next fiscal year.

GH Research Price Performance

GHRS stock opened at $20.71 on Thursday. The firm has a market capitalization of $1.42 billion, a P/E ratio of -20.71 and a beta of 1.32. The business’s 50-day moving average is $24.38 and its two-hundred day moving average is $21.44. GH Research has a 1 year low of $12.04 and a 1 year high of $31.44.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on GHRS. Weiss Ratings reissued a “sell (d-)” rating on shares of GH Research in a research report on Thursday, October 15th. Guggenheim upped their target price on shares of GH Research from $34.00 to $40.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Needham & Company LLC raised their target price on shares of GH Research from $32.00 to $39.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Zacks Research raised shares of GH Research from a “strong sell” rating to a “hold” rating in a report on Thursday, August 13th. Finally, Wall Street Zen downgraded shares of GH Research from a “hold” rating to a “sell” rating in a research note on Saturday, October 24th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $45.00.

GH Research Company Profile

GH Research plc is a clinical-stage biopharmaceutical company focused on developing novel therapies for psychiatric and neurological disorders. The company is headquartered in Dublin, Ireland, and conducts research and clinical development activities through its proprietary pipeline of psychedelic-based medicines.

Its lead program, GH001, is an investigational inhaled formulation of mebufotenin, also known as 5-MeO-DMT. GH Research has studied GH001 in patients with treatment-resistant depression, with the aim of developing a rapidly acting treatment that may provide meaningful improvements following a short course of administration.